New tests launched in September
New Tests
In September 2022, Mayo Clinic Laboratories announced ten new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in September 2022 by Mayo Clinic Laboratories:
BRBPS | Broad Range Bacterial PCR and Sequencing, Varies
This test is intended for detecting and identifying bacteria (including mycobacteria) from normally sterile sources, including synovial fluid; body fluids such as pleural, peritoneal, and pericardial fluids, cerebrospinal fluid; and both fresh and formalin-fixed paraffin-embedded tissues.
C1INF | C1 Esterase Inhibitor, Functional, Serum
This test is intended for diagnosing hereditary angioedema, and monitoring response to C1 esterase inhibitor replacement therapy.
FLACQ | Lactoferrin, Quantitative, Stool
HEVQU | Hepatitis E Virus RNA Detection and Quantification, Real-Time RT-PCR, Serum
This test is intended for Virologic detection and confirmation of hepatitis E virus (HEV) infection in individuals who are immunocompromised and are at risk for or suspected to have acute or chronic hepatitis E.
KLF1 | KLF1 Full Gene Sequencing, Varies
This test is intended for aiding in the diagnosis and carrier detection of KLF1 sequence alterations that are reported to be responsible for neonatal anemia or jaundice, hydrops fetalis, increased fetal hemoglobin and hemoglobin A2.
MSUSC | Branched-Chain Amino Acids, Self-Collect, Blood Spot
This test is intended for monitoring patients with maple-syrup urine disease using specimens collected at home.
PETH | Phosphatidylethanol Confirmation, Blood
This test is intended for verifying abstinence or use of ethanol especially in liver transplant candidates/patients
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories: